This week's quotation: "It's no wonder that truth is stranger than fiction. Fiction has to make sense." - Mark Twain
In this week's #TWiV clinical update, Dr. Daniel Griffin & Dr. Vincent Racaniello are alarmed at how #RFKJr is breaking his promise of not altering vaccine policies, and nonexistent data and studies are used by members of the #ACIP to make changes to immunization practices in the absence of a #CDC director, justification for not honoring the US commitment to #GAVI and global #publicHealth policies including support of routine childhood immunizations, placing millions of children at risk for the return of vaccine preventable diseases including polio outbreaks in Pappa New Guinea and increased circulation of wildtype type 1 poliovirus, before Dr. Griffin reviews recent statistics on RSV, influenza and SARS-CoV-2 infections, the Wastewater Scan dashboard, approval of Merck’s anti-RSV mRNA monoclonal antibody, whether or not the NB.1.8.1 should be included in the fall 2025 #vaccines, #immunization recommendations for COVID-19 vaccines, where to find #PEMGARDA, changes in COVID mRNA vaccine labeling and reframing of the science around the vaccine, provides information for Columbia University Irving Medical Center’s long #COVID treatment center, where to go for answers to your #longCOVID questions, and contacting your federal government representative to stop the assault on #science and biomedical research.
https://www.youtube.com/watch?v=lvjItbi_6sQ
Page with source links: https://www.microbe.tv/twiv/twiv-1230/
TWiV 1230: Clinical update with Dr. Daniel Griffin

YouTube
Unfortunately #pemgarda works less well for JN.1.1 & worse for KP.x & Sipavibart/evusheld doesn't work at all for KP.x according to this preprint: https://www.biorxiv.org/content/10.1101/2024.08.20.608835v1.full.pdf I had an appointment for next week but :( thinking the risk of side effects aren't worth it.

Many patients who are interested in Pemgarda have been unable to get it because of lack of awareness among doctors, a limited number of infusion centers administering it, eligibility criteria, and insurance denials.

https://thesicktimes.org/2024/07/30/frustrations-denials-long-drives-immunocompromised-people-cant-access-a-lifesaving-covid-19-drug/

#Covid #Pemgarda #CovidPrep

Frustrations, denials, long drives: Immunocompromised people can’t access a lifesaving Covid-19 drug - The Sick Times

A new drug approved months ago to help prevent Covid-19 infections could be a game changer for high-risk people — if they can get their hands on it. But many say they have struggled to access the medication.

The Sick Times - Chronicling the Long Covid crisis

FDA OKs New Drug To Boost #COVID19 Protection for Immunocompromised People

"People with severely compromised immune systems may need regular infusions."

"#Pemgarda, made by the company Invivyd, is a successor to the previous monoclonal antibody #Evusheld, which was withdrawn from use by the FDA in January of 2023 when it became clear that it was not effective against new COVID-19 variants."

https://www.healthline.com/health-news/fda-oks-new-drug-to-boost-covid-19-protection-for-immunocompromised-people

#ABCovid

FDA OKs New Drug To Boost COVID-19 Protection for Immunocompromised People

The FDA granted an emergency use authorization for Pemgarda, a monoclonal antibody for people who are immunocompromised to provide protection from COVID-19.

Healthline Media